Provided by Tiger Fintech (Singapore) Pte. Ltd.

RxSIGHT, INC.

14.43
-0.0950-0.65%
Post-market: 14.430.00000.00%17:40 EDT
Volume:1.07M
Turnover:15.44M
Market Cap:584.28M
PE:-20.43
High:14.77
Open:14.49
Low:14.35
Close:14.53
Loading ...

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

MT Newswires Live
·
21 Dec 2024

RxSight Down Over 13%, on Pace for Largest Percent Decrease Since June 2022 -- Data Talk

Dow Jones
·
21 Dec 2024

RxSight Shares Fall After Stifel Downgrade

MT Newswires Live
·
21 Dec 2024

Hold Rating Issued Amidst Rising Competition and Market Uncertainty for RxSight

TIPRANKS
·
21 Dec 2024

Do You Believe in the Long-Term Growth Potential of RxSight (RXST)?

Insider Monkey
·
20 Dec 2024

Stifel Downgrades RxSight to Hold From Buy, Adjusts Price Target to $40 From $65

MT Newswires Live
·
20 Dec 2024

Positive week for RxSight, Inc. (NASDAQ:RXST) institutional investors who lost 1.6% over the past year

Simply Wall St.
·
20 Dec 2024

Wells Fargo Downgrades RxSight to Equal Weight From Overweight, $56 Price Target

MT Newswires Live
·
11 Dec 2024

UBS Initiates RxSight at Buy With $52 Price Target

MT Newswires Live
·
06 Dec 2024

Rxsight Inc : UBS Initiates Coverage With Buy Rating and Target Price $52

THOMSON REUTERS
·
06 Dec 2024

RxSight initiated with a Buy at UBS

TIPRANKS
·
06 Dec 2024

RxSight’s Promising Growth with Light Adjustable Lens: A Buy Recommendation by Danielle Antalffy

TIPRANKS
·
06 Dec 2024

3 ‘Buy’ stocks and 2 ‘Hold’ stocks according to Oppenheimer

seekingalpha
·
22 Nov 2024

RxSight (RXST) Upgraded to Buy: Here's What You Should Know

Zacks
·
21 Nov 2024

RxSight (RXST) Gets a Buy from BTIG

TIPRANKS
·
10 Nov 2024

Rxsight Inc reports results for the quarter - Earnings Summary

Reuters
·
09 Nov 2024

RxSight Inc (RXST) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Market ...

GuruFocus.com
·
09 Nov 2024

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Artivion (AORT) and RxSight (RXST)

TIPRANKS
·
08 Nov 2024

RxSight’s Strong Growth and Market Positioning Earns Buy Rating from Analyst

TIPRANKS
·
08 Nov 2024

RxSight Q3 2024 Adj EPS $0.00 Beats $(0.25) Estimate, Sales $35.31M Beat $35.06M Estimate

Benzinga
·
08 Nov 2024